AnaptysBio
ANAB
132 hedge funds and large institutions have $429M invested in AnaptysBio in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 51 reducing their positions, and 13 closing their positions.
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
8% more funds holding
Funds holding: 122 → 132 (+10)
3.3% less ownership
Funds ownership: 109.96% → 106.66% (-3.3%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
36% less capital invested
Capital invested by funds: $670M → $429M (-$241M)
39% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 51
98% less call options, than puts
Call options by funds: $25K | Put options by funds: $1.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$6.65M |
| 2 |
Millennium Management
New York
|
+$3.09M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.68M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$2.09M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.71M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.38M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.25M |
| 4 |
O
OrbiMed
New York
|
-$3.52M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.45M |
ANAB Hedge Fund Activity: Q3 2020 in Review
132 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2020, worth a combined $429M — down 36% from $670M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ANAB positions and 13 closed out — a net gain of 10 holders — while 31 added to existing stakes and 51 trimmed.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $6.65M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.71M sold.
- 132 institutional investors held AnaptysBio (ANAB) as of Q3 2020, up from 122 in Q2 2020.
- Funds reported $429M of AnaptysBio stock for Q3 2020, down 36% quarter-over-quarter.
- 23 funds opened new AnaptysBio positions in Q3 2020 and 13 closed out, a net change of +10 holders.
- The largest AnaptysBio buyer in Q3 2020 was Palo Alto Investors, an estimated $6.65M added.
- The largest AnaptysBio seller in Q3 2020 was Point72 Asset Management, an estimated $4.71M sold.
Based on aggregated 13F filings for Q3 2020.